Alerts will be sent to your verified email
Verify Email
IGCIL
|
IGC Industries
|
Vivanza Biosciences
|
EVOQ Remedies
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-23.7 % | 4.27 % | 21.9 % |
|
5yr average Equity Multiplier
|
10.25 | 4.19 | 3.25 |
|
5yr Average Asset Turnover Ratio
|
0.01 | 0.9 | 0.54 |
|
5yr Avg Net Profit Margin
|
-377.91 % | 0.04 % | 6.7 % |
|
Price to Book
|
0.19 | 1.73 | 0.18 |
|
P/E
|
0.0 | 0.0 | 88.0 |
|
5yr Avg Cash Conversion Cycle
|
94.14 Days | 296.4 Days | 149.18 Days |
|
Inventory Days
|
2354.37 Days | 53.72 Days | 70.89 Days |
|
Days Receivable
|
182.72 Days | 481.83 Days | 160.81 Days |
|
Days Payable
|
625.9 Days | 199.57 Days | 163.4 Days |
|
5yr Average Interest Coverage Ratio
|
-227.75 | 1.5 | 2683.3 |
|
5yr Avg ROCE
|
-23.16 % | 12.63 % | 29.29 % |
|
5yr Avg Operating Profit Margin
|
-379.31 % | 0.66 % | -11.9 % |
|
5 yr average Debt to Equity
|
0.0 | 1.39 | 0.18 |
|
5yr CAGR Net Profit
|
-28.0 % | n/a | -34.02 % |
|
5yr Average Return on Assets
|
-1.87 % | 0.88 % | 3.64 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 20.02 % | 11.21 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-65.49 % | -27.78 % | -62.32 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
IGC Industries
|
Vivanza Biosciences
|
EVOQ Remedies
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|